DA
CYTR

Dunvegan Associates’s CytRx Corp CYTR Stock Holding History

Dunvegan Associates’s Portfolio CYTR Stock Details CYTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-8,007
Closed -$155K – 79
2013
Q3 		$155K Hold
8,007
– – 0.11% 75
2013
Q2 		$96K Buy
+8,007
New +$118K 0.07% 74

Other funds holding CYTR

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dunvegan Associates's CYTR Position: Q4 2013 in Review

Dunvegan Associates sold out of CytRx Corp (CYTR) in Q4 2013, closing a stake of 8,007 shares — an estimated $155K sold.

Dunvegan Associates first reported a position in CYTR in Q2 2013 and held it in 2 quarters. The position peaked at $155K in Q3 2013. 47 funds tracked by Wall St. Rank hold CYTR as of Q4 2013.

  • Dunvegan Associates reported no remaining CytRx Corp position as of Q4 2013 after selling out during the quarter.
  • Dunvegan Associates sold 8,007 CytRx Corp shares in Q4 2013, an estimated $155K.
  • Dunvegan Associates first reported a position in CytRx Corp in Q2 2013 and held it in 2 quarters.
  • Dunvegan Associates's CytRx Corp position peaked at $155K in Q3 2013.
  • 47 funds tracked by Wall St. Rank held CytRx Corp as of Q4 2013.

Based on Dunvegan Associates's 13F filing for Q4 2013, filed 21 Feb 2014.